A Bright Future Lies Ahead for Molecular Imaging

2,225 views

Published on

An analyst briefing presentation delivered by Roberto Aranibar, research analyst in Frost & Sullivan's medical imaging group.

Published in: Health & Medicine
2 Comments
2 Likes
Statistics
Notes
  • Thank you for your kind words! Would you like more information about this research from Frost & Sullivan?
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • I was very encouraged to find this site. I wanted to thank you for this special read. I definitely savored every little bit of it.

    Holistic Healing
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
No Downloads
Views
Total views
2,225
On SlideShare
0
From Embeds
0
Number of Embeds
5
Actions
Shares
0
Downloads
17
Comments
2
Likes
2
Embeds 0
No embeds

No notes for slide

A Bright Future Lies Ahead for Molecular Imaging

  1. 1. A Bright Future Lies Ahead for Molecular Imaging Roberto G. Aranibar, Research Analyst Medical Imaging February 9, 2011
  2. 2. Today’s Presenters Roberto G. Aranibar, Research Analyst Frost & Sullivan 2
  3. 3. IntroductionAgendaI. Molecular Imaging (MI): Introduction and BackgroundII. Ongoing Developments in MI 3
  4. 4. Molecular Imaging (MI): Introduction and Background 4
  5. 5. Molecular Imaging (MI) Molecular imaging in cardiac, pulmonary, and neurological imaging applications Source: www.snm.org• Definition• Unique Advantages• Tools & Objective• Modalities/Techniques • Nuclear Medicine • Scintigraphy • SPECT • PET • Optical (Preclinical) The power of molecular imaging. A patient with a history of breast • Fluorescence cancer is suspected of having a chest wall recurrence. CT was indeterminate, but PET was clearly positive. Source: • Bioluminescence www.cancernetwork.com • Hybrid Techniques 5
  6. 6. Clinical MI Market Performance (U.S.) Nuclear Medicine PETKey Clinical MI Markets 600• NM 500 Revenues ($ Million)• PET 400 300 200General Trend 100• Downward since 2003 0 97 98 99 00 01 02 03 04 05 06 07 08 09 10 19 19 19 20 20 20 20 20 20 20 20 20 20 20Outlook Annual Revenues in Key Clinical MI Markets (U.S., new equipment only). Source: Frost & Sullivan• 2010?• 2011 and beyond? 6
  7. 7. Ongoing Developments in Molecular Imaging 7
  8. 8. Increased Access to MIAvailability of Radiopharmaceuticals• Expanding Radiopharmacy Networks• More Affordable Costs• Increased Efforts to Secure Supply of Medical RadioisotopesAccess to MI Research Tools• Small, Simple and Affordable MI Solutions Map of commercial cyclotron/FDG radiopharmacies in the United States. Source: UCLA Sofie Biosciences’ Benchtop Preclinical PET Imaging Solution. Source: www.sofiebio.com 8
  9. 9. Novel ProbesNuclear Radioisotopes• For Neurology • Amyvid (PET) • 18F-Flutemetamol (PET) • DaTSCAN (SPECT) • 18F-AV-133 (SPECT)• For Oncology • Hypoxia Agents 18F-FMISO (PET) • 18F-FLTOptical Fluorescence• For Intraoperative Cancer Visualization • Chlorotoxin-Cy5.5 Source: www.chem.monash.edu 9
  10. 10. New Instrument Technologies• New Solid-State Technologies• Whole-body PET/MR Imaging Solutions GE Healthcare’s PET/CT+MRI Tri-modality Solution. Source: GE Healthcare Philips Healthcare’s Ingenuity TF PET/MR Siemens Healthcare’s Biograph mMR System. Source: www.gezondheidskrant.nl/ Scanner. Source: Siemens Healthcare 10
  11. 11. Other Ongoing DevelopmentsEmerging Clinical Applications• Molecular Breast Imaging (MBI) • PEM (Positron Emission Mammography) • BSGI (Breast-Specific Gamma Imaging)• Dedicated Cardiac PET The Naviscan PEM Scanner for detection, The Dilon 6800 BSGI Camera. staging, and management of breast cancer. Source: www.dilon.com Source: www.naviscan.comExpanding Reimbursement Coverage• April 2009 – FDG-PET for an expanded set of cancer indications• February 2011 – 18F-NaF Positron’s Attrius Cardiac PET Scanner. Source: www.positron.com 11
  12. 12. Conclusion Nuclear Medicine PETMarket Outlook 600• NM 500 Revenues ($ Million)• PET 400 300 200 100 0 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 19 19 19 20 20 20 20 20 20 20 20 20 20 20 20 Annual Revenues in Key Clinical MI Markets and Preliminary Outlook (U.S., new equipment only). Source: Frost & Sullivan 12
  13. 13. Next Steps Request a proposal for or Growth Partnership Services or Growth Consulting Services to support you and your team to accelerate the growth of your company. (myfrost@frost.com) 1-877-GoFrost (1-877-463-7678) Join us at our annual Growth, Innovation, and Leadership 2011: A Frost & Sullivan Global Congress on Corporate Growth, September 11-14 2011, Fairmont San Jose, San Jose, CA (www.gil-global.com) Register for Frost & Sullivan’s Growth Opportunity Newsletter and keep abreast of innovative growth opportunities (www.frost.com/news) 13
  14. 14. Your Feedback is Important to Us What would you like to see from Frost & Sullivan?Growth Forecasts?Competitive Structure?Emerging Trends?Strategic Recommendations?Other? Please inform us by Rating this Presentation. Frost & Sullivan’s Growth Consulting can assist with your growth strategies 14
  15. 15. Follow Frost & Sullivan on Facebook, LinkedIn,SlideShare, and Twitter http://www.facebook.com/FrostandSullivan http://www.linkedin.com/companies/4506 http://www.slideshare.net/FrostandSullivan http://twitter.com/frost_sullivan 15
  16. 16. For Additional InformationBritni Myers Angie MontoyaCorporate Communications Global Analyst Briefing CoordinatorHealthcare Marketing(210) 477-8481 (210) 247-2435Britni.myers@frost.com amontoya@frost.comAntonio Garcia Carol SklossResearch Manager Sales ManagerMedical Imaging Healthcare(210) 247-3886 (210) 247-3810Antonio.garcia@frost.com cskloss@frost.com 16

×